MetaCap

Quanterix Corporation (QTRX)

NASDAQ: QTRXIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

1.96-0.07 (-3.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QTRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$93.06M
EPS (TTM)
-$2.34
52-week range
1.77 – 8.77
Day range
1.78 – 2.03
Volume / Avg
1.06M / 721.60K
Beta
—

52-week range

$1.77$8.77

QTRX stock today

Shares of Quanterix (QTRX) finished lower on Nov 20 at $1.96, a drop of 3.45% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 77.7% below their 52-week high of $8.77, set on Jan 9, 2026 and 11.0% above the 52-week low of $1.77, near the bottom of the past year's range. QTRX is down 69.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 70.6%.

Quanterix has posted a net loss over the last twelve months (EPS of -$2.34), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Quanterix

Company profile

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Everett V. Cunningham
Headquarters
Billerica, MA
Employees
450
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Quanterix generated $138.9 million in revenue, up 1.1% from fiscal 2024, its 3rd consecutive year of revenue growth. Quanterix reported a net loss of $107.2 million, compared with a loss of $38.5 million a year earlier. Gross margin was 46.8% (down from 60.5%) and operating margin -90.4%.

Quanterix annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$138.90M$137.42M$122.37M$105.52M$110.56M
Growth+1.07%+12.30%+15.96%-4.55%+27.99%
Net income$-107.15M$-38.53M$-28.35M$-99.57M$-55.55M
EPS (diluted)$-2.51$-1.00$-0.75$-2.69$-1.54

Analyst forecast

Forecast

Consensus (3 analysts)

hold

Avg. price target

$3.33+69.90%

  • Strong buy 0
  • Buy 0
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $4.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.46 vs —

QTRX news

All QTRX news

Quanterix peers

Industrials sector
QTRX peer companies
CompanyPrice% ChgMarket capCompare
SEERSeer Inc. Class A1.36-1.81%$75.91Mvs QTRX
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs QTRX
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs QTRX
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs QTRX
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs QTRX
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs QTRX
BNGOBionano Genomics Inc.0.8222-7.11%$11.50Mvs QTRX
ASTCAstrotech Corporation (DE)3.50-0.85%$7.45Mvs QTRX

Indexes, lists and sector

Quanterix stock FAQ

What is Quanterix's stock price today?

QTRX last traded at $1.96 as of Nov 20, 4:00 PM EST, down 3.45% on the day. Prices are delayed at least 15 minutes.

Who is Quanterix's CEO?

Mr. Everett V. Cunningham is the chief executive officer of Quanterix Corporation, which has about 450 employees.

What is the QTRX 52-week high?

The 52-week high for QTRX is $8.77 and the 52-week low is $1.77. The stock is currently 77.7% below its high.

Compare QTRX